The network meta-analysis and GRADE assessment showed that both SGLT-2 inhibitors and GLP-1 receptor agonists reduce all-cause mortality, cardiovascular mortality, non-fatal myocardial infarction, and kidney failure. The gene discussed is SLC5A2; the disease is kidney failure.